Nektar Therapeutics (NKTR) Misses Q1 EPS by 7c, Revenues Beat
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $59.38 +0.29%
Revenue Growth %: +141.7%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +141.7%
Financial Fact:
Interest expense: -5.61M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.78), $0.07 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $50.57 million versus the consensus estimate of $47.64 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
- Starbucks designates Val Bauduin as principal accounting officer
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
